Financials

v3.21.2
CONDENSED BALANCE SHEETS - USD ($)
$ in Thousands
Sep. 30, 2021
Dec. 31, 2020
Current assets:    
Cash and cash equivalents $ 7,418 $ 5,413
Receivables 265 884
Inventory 129 328
Prepaid expenses and other current assets 846 522
Discontinued operations - current assets 187 181
Total current assets 8,845 7,328
Property and equipment, net 468 618
Operating lease right-of-use asset 324 141
Total assets 9,637 8,087
Current liabilities:    
Accounts payable 386 1,253
Accrued clinical trials expenses 14 214
Other accrued liabilities 303 319
Operating lease liability, current 109 150
Current portion of long-term debt 0 327
Discontinued operations - current liabilities 1,113 1,960
Total current liabilities 1,925 4,223
Operating lease liability, noncurrent 216 0
Long-term debt 0 332
Total liabilities 2,141 4,555
Commitments and contingencies (Note 6)
Stockholders' equity:    
Common stock, at amounts paid-in, $0.001 par value per share; 225,000,000 shares authorized 9,864,158 and 7,139,068 shares issued and outstanding at September 30, 2021 and December 31, 2020, respectively 10 7
Additional paid-in capital 381,001 370,804
Accumulated deficit (373,515) (367,279)
Total stockholders' equity 7,496 3,532
Total liabilities and stockholders' equity $ 9,637 $ 8,087

Source

v3.21.2
CONDENSED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2021
Sep. 30, 2020
Sep. 30, 2021
Sep. 30, 2020
Revenues:        
Total revenues $ 264 $ 1,018 $ 1,391 $ 3,393
Operating expenses:        
Cost of goods sold 0 0 199 0
Research and development 1,193 887 4,716 4,343
Selling, general and administrative 979 1,327 3,341 4,052
Total operating expenses 2,172 2,214 8,256 8,395
Loss from operations (1,908) (1,196) (6,865) (5,002)
Other income (expense):        
Interest expense, net 0 (246) (2) (718)
Non-cash loss on changes in the fair value of warrants 0 0 0 (923)
Gain on debt extinguishment 0 0 661 0
Other expense, net (7) (13) (30) (233)
Other income (expense), net (7) (259) 629 (1,874)
Loss from continuing operations (1,915) (1,455) (6,236) (6,876)
Loss from discontinued operations 0 (3,477) 0 (8,281)
Net loss and comprehensive loss $ (1,915) $ (4,932) $ (6,236) $ (15,157)
Basic and diluted net loss per common share from continuing operations $ (0.19) $ (0.45) $ (0.64) $ (2.25)
Basic and diluted net loss per common share from discontinued operations $ 0 $ (1.07) $ 0 $ (2.70)
Weighted average shares used in computing basic net loss per common share 9,864 3,264 9,675 3,062
Weighted average shares used in computing diluted net loss per common share 9,864 3,264 9,675 3,062
License revenue        
Revenues:        
Total revenues $ 4 $ 0 $ 9 $ 6
Product revenue        
Revenues:        
Total revenues 36 0 236 39
Grant revenue        
Revenues:        
Total revenues $ 224 $ 1,018 $ 1,146 $ 3,348

Source

v3.21.2
CONDENSED STATEMENTS OF CASH FLOWS - USD ($)
$ in Thousands
9 Months Ended
Sep. 30, 2021
Sep. 30, 2020
Cash flows from operating activities:    
Net loss $ (6,236) $ (15,157)
Adjustments to reconcile net loss to net cash used in operating activities:    
Depreciation and amortization 168 227
Non-cash interest expense 2 447
Non-cash loss on changes in fair value of warrants 0 923
Non-cash loss on asset impairment 0 433
Non-cash gain on debt extinguishment (661) 0
Stock-based compensation 1,359 4
Finance costs attributable to issuance of warrants 0 211
Other (8) (11)
Changes in operating assets and liabilities:    
Receivables 459 570
Inventory 199 (508)
Prepaid expenses and other assets (170) 14
Accounts payable (1,628) 309
Accrued sales allowances 0 (690)
Other accrued liabilities (302) 586
Net cash used in operating activities (6,818) (12,642)
Cash flows from investing activities:    
Purchases of property and equipment (18) (531)
Net cash used in investing activities (18) (531)
Cash flows from financing activities:    
Net proceeds from equity offering 8,841 4,339
Net proceeds from the exercises of common stock warrants 0 7,030
Net loan proceeds 0 654
Net cash provided by financing activities 8,841 12,023
Net increase (decrease) in cash and cash equivalents 2,005 (1,150)
Cash and cash equivalents at beginning of period 5,413 5,223
Cash and cash equivalents at end of period 7,418 4,073
Supplemental disclosure of cash flow information:    
Interest paid $ 0 $ 295

Source